| First round % (n) | Second round % (n) | Third round % (n) | |
| Uptake | |||
| Total | 55.0 (304245) | 53.0 (309803) | 55.3 (317864) |
| Males | 50.4 (150201) | 48.7 (153359) | 51.0 (158065) |
| Females | 59.5 (154044) | 57.1 (156444) | 59.6 (159799) |
| Response to first kit | 43.8 (304245) | 51.5 (309803) | 53.7 (317864) |
| Non-responders in all previous rounds | – | 13.8 (111763) | 13.9 (105115) |
| Responders in any previous round | – | 85.4 (147469) | 85.2 (158006) |
| Positivity rate | |||
| Total | 2.07 (167415) | 1.90 (164077) | 1.16 (175853) |
| Males | 2.83 (75724) | 2.56 (74686) | 1.52 (80624) |
| Females | 1.44 (91691) | 1.36 (89391) | 0.86 (95229) |
| Non-responders in all previous rounds | – | 2.56 (15401) | 1.58 (14660) |
| Responders in any previous round | – | 1.88 (125989) | 1.10 (134671) |
The differences between males and females in all rounds and in both parameters were statistically significant at the p<0.001 level, and the decline of the positivity rate was statistically significant at the p<0.01 level (χ2 test).